18
Participants
Start Date
August 31, 2018
Primary Completion Date
July 30, 2020
Study Completion Date
July 30, 2020
IL-1 receptor antagonist Anakinra
IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
University Hospital Basel Endocrinology, Diabetes and Metabolism, Basel
University Hospital, Basel, Switzerland
OTHER